Global X Genomics & Biotechnology ETF
GNOM
Market cap $69.9M

9.89 USD

+0.19

1.96%

At close Dec 20, 4:00 PM EST

1 day

1.96%

5 days

-3.70%

1 month

0.71%

3 months

-12.63%

6 months

-2.56%

Year to date

-15.33%

1 year

-11.14%

5 years

-38.23%

10 years

-35.65%

0

Funds holding %

of 6,809 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

17% more capital invested

Capital invested by funds: $29.9M [Q2] → $35M (+$5.06M) [Q3]

10.23% more ownership

Funds ownership: 31.47% [Q2] → 41.69% (+10.23%) [Q3]

5% less funds holding

Funds holding: 64 [Q2] → 61 (-3) [Q3]

20% less repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 20

30% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 10

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for GNOM.

See Analyst Rankings

Financial journalist opinion

Zacks Investment Research

Best-Performing ETF Areas of Last Week

Wall Street was upbeat last week with the Dow Jones and the S&P 500 hitting all-time highs last week.

Best-Performing ETF Areas of Last Week

The 3 Best Gene Editing Stocks to Buy in July 2024

Gene editing is revolutionizing medicine, creating substantial opportunities for some of the best gene editing stocks. With the technology, we can fix faulty genes, or replace them with healthier genes in an attempt to cure diseases or help the body fight disease.

The 3 Best Gene Editing Stocks to Buy in July 2024

Genomics Game-Changers: 3 Stocks Unlocking the Secrets of Life

Genomics is the future of medicine. With it, companies are racing to shed light on human health and disease.

3 Gene Editing Stocks with the Potential to Make You an Overnight Millionaire

Pay close attention to gene editing stocks. By 2028, according to MarketsandMarkets, the market could be worth about $10.6 billion from $5.3 billion in 2023.

GNOM: Genomics Still Waiting For Its 'ChatGPT' Moment

GNMO invests across companies benefiting from advancements in the field of genomics within biotechnology. The fund's historical performance has been poor amid volatile stock prices for underlying holdings. Genomics may be the future, but still missing a blockbuster application to drive a wave of bullish momentum into the segment.

3 Stocks That Could Be the Next Big Thing in Gene Editing

Gene editing could revolutionize how millions of patients are treated all over the world. That could create big opportunities for some of the most exciting gene-editing stocks.

3 Gene Editing Stocks With Unprecedented Surge Potential

Gene editing is revolutionizing medicine. For example, just weeks ago, the U.S. Federal Drug Administration approved a new gene-editing treatment for sickle cell disease and transfusion-dependent beta-thalassemia, a genetic disorder that prevents the production of hemoglobin in the blood and requires regular blood transfusions.

3 Once-in-a-Lifetime Gene Editing Stocks with Unprecedented Surge Potential

Some of the top gene-editing stocks have had immense surge potential. Look at CRISPR Therapeutics (NASDAQ: CRSP ), for example.

VettaFi Voices On: The Outlook for 2024

Good morning, VettaFi Voices! We are a week out from the VettaFi 2024 Market Outlook Symposium on December 14, which will feature a range of ETF industry leaders discussing their expectations for different areas of the financial markets and the economy in 2024.

VettaFi Voices On: The Outlook for 2024

See News Rankings

Charts implemented using Lightweight Charts™